Expression of Monocarboxylate Transporter 1 in Immunosuppressive Macrophages Is Associated With the Poor Prognosis in Breast Cancer

Overview

Journal Front Oncol

Specialty Oncology

Date 2020 Nov 12

PMID 33178603

Citations 14

Authors

Bei Li

Qian Yang

Zhiyu Li

Zhiliang Xu

Si Sun

Qi Wu

Shengrong Sun

Affiliations

Soon will be listed here.

Abstract

Monocarboxylate transporter 1 (MCT1) participates in the transport of lactate to facilitate metabolic reprogramming during tumor progression. Tumor-associated macrophages (TAMs) are also involved in the inflammatory adaptation of the tumor microenvironment (TME). This study aimed to determine the correlation between metabolite changes and the polarization of macrophages in the TME. We demonstrated that the expression of CD163 on macrophages was significantly higher in breast cancer tissues than in normal tissues, especially in the HER2 subtype, although it was not statistically associated with recurrence-free survival (RFS). The presence of MCT1 and CD163 macrophages in the invasive margin was significantly correlated with decreased RFS. A significant correlation existed between MCT1 and CD163 expression in the margin, and high infiltration of MCT1CD163 macrophages into the margin predicted rapid progression and poor survival outcomes for breast cancer patients. These data suggested that MCT1 at least partially promoted the alternative polarization of macrophages to inhibit antitumor immunity, and blocking this interaction may be a promising method for breast cancer therapy.

Citing Articles

Macrophage Polarisation in the Tumour Microenvironment: Recent Research Advances and Therapeutic Potential of Different Macrophage Reprogramming.

Guo R, Wang R, Zhang W, Li Y, Wang Y, Wang H Cancer Control. 2025; 32:10732748251316604.

PMID: 39849988 PMC: 11758544. DOI: 10.1177/10732748251316604.

Involvement of tumor immune microenvironment metabolic reprogramming in colorectal cancer progression, immune escape, and response to immunotherapy.

Nicolini A, Ferrari P Front Immunol. 2024; 15:1353787.

PMID: 39119332 PMC: 11306065. DOI: 10.3389/fimmu.2024.1353787.

Immune Features of Tumor Microenvironment: A Genetic Spotlight.

Asadi M, Zarredar H, Zafari V, Soleimani Z, Saeedi H, Caner A Cell Biochem Biophys. 2023; 82(1):107-118.

PMID: 37870699 DOI: 10.1007/s12013-023-01192-7.

Unveiling the veil of lactate in tumor-associated macrophages: a successful strategy for immunometabolic therapy.

Tao H, Zhong X, Zeng A, Song L Front Immunol. 2023; 14:1208870.

PMID: 37564659 PMC: 10411982. DOI: 10.3389/fimmu.2023.1208870.

Unveiling tumor immune evasion mechanisms: abnormal expression of transporters on immune cells in the tumor microenvironment.

Chen L, Wang Y, Hu Q, Liu Y, Qi X, Tang Z Front Immunol. 2023; 14:1225948.

PMID: 37545500 PMC: 10401443. DOI: 10.3389/fimmu.2023.1225948.

References

Fischer K, Hoffmann P, Voelkl S, Meidenbauer N, Ammer J, Edinger M . Inhibitory effect of tumor cell-derived lactic acid on human T cells. Blood. 2007; 109(9):3812-9. DOI: 10.1182/blood-2006-07-035972. View

Sanita P, Capulli M, Teti A, Paradiso Galatioto G, Vicentini C, Chiarugi P . Tumor-stroma metabolic relationship based on lactate shuttle can sustain prostate cancer progression. BMC Cancer. 2014; 14:154. PMC: 3945608. DOI: 10.1186/1471-2407-14-154. View

Xu M, Liu M, Du X, Li S, Li H, Li X . Intratumoral Delivery of IL-21 Overcomes Anti-Her2/Neu Resistance through Shifting Tumor-Associated Macrophages from M2 to M1 Phenotype. J Immunol. 2015; 194(10):4997-5006. DOI: 10.4049/jimmunol.1402603. View

Colegio O, Chu N, Szabo A, Chu T, Rhebergen A, Jairam V . Functional polarization of tumour-associated macrophages by tumour-derived lactic acid. Nature. 2014; 513(7519):559-63. PMC: 4301845. DOI: 10.1038/nature13490. View

Wu Q, Li B, Li Z, Li J, Sun S, Sun S . Cancer-associated adipocytes: key players in breast cancer progression. J Hematol Oncol. 2019; 12(1):95. PMC: 6734503. DOI: 10.1186/s13045-019-0778-6. View

Payen V, Mina E, Van Hee V, Porporato P, Sonveaux P . Monocarboxylate transporters in cancer. Mol Metab. 2019; 33:48-66. PMC: 7056923. DOI: 10.1016/j.molmet.2019.07.006. View

Pinheiro C, Longatto-Filho A, Azevedo-Silva J, Casal M, Schmitt F, Baltazar F . Role of monocarboxylate transporters in human cancers: state of the art. J Bioenerg Biomembr. 2012; 44(1):127-39. DOI: 10.1007/s10863-012-9428-1. View

Denkert C, von Minckwitz G, Darb-Esfahani S, Lederer B, Heppner B, Weber K . Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol. 2017; 19(1):40-50. DOI: 10.1016/S1470-2045(17)30904-X. View

Chavey C, Bibeau F, Gourgou-Bourgade S, Burlinchon S, Boissiere F, Laune D . Oestrogen receptor negative breast cancers exhibit high cytokine content. Breast Cancer Res. 2007; 9(1):R15. PMC: 1851386. DOI: 10.1186/bcr1648. View

10.

Park J, Sung J, Lee J, Park Y, Kim Y, Kim G . Polarized CD163+ tumor-associated macrophages are associated with increased angiogenesis and CXCL12 expression in gastric cancer. Clin Res Hepatol Gastroenterol. 2015; 40(3):357-365. DOI: 10.1016/j.clinre.2015.09.005. View

11.

Ohno S, Ohno Y, Suzuki N, Kamei T, Koike K, Inagawa H . Correlation of histological localization of tumor-associated macrophages with clinicopathological features in endometrial cancer. Anticancer Res. 2004; 24(5C):3335-42. View

12.

Pinheiro C, Miranda-Goncalves V, Longatto-Filho A, Vicente A, Berardinelli G, Scapulatempo-Neto C . The metabolic microenvironment of melanomas: Prognostic value of MCT1 and MCT4. Cell Cycle. 2016; 15(11):1462-70. PMC: 4934068. DOI: 10.1080/15384101.2016.1175258. View

13.

Jackute J, Zemaitis M, Pranys D, Sitkauskiene B, Miliauskas S, Vaitkiene S . Distribution of M1 and M2 macrophages in tumor islets and stroma in relation to prognosis of non-small cell lung cancer. BMC Immunol. 2018; 19(1):3. PMC: 5781310. DOI: 10.1186/s12865-018-0241-4. View

14.

Zhao X, Qu J, Sun Y, Wang J, Liu X, Wang F . Prognostic significance of tumor-associated macrophages in breast cancer: a meta-analysis of the literature. Oncotarget. 2017; 8(18):30576-30586. PMC: 5444766. DOI: 10.18632/oncotarget.15736. View

15.

Jackaman C, Tomay F, Duong L, Abdol Razak N, Pixley F, Metharom P . Aging and cancer: The role of macrophages and neutrophils. Ageing Res Rev. 2017; 36:105-116. DOI: 10.1016/j.arr.2017.03.008. View

16.

Wilde L, Roche M, Domingo-Vidal M, Tanson K, Philp N, Curry J . Metabolic coupling and the Reverse Warburg Effect in cancer: Implications for novel biomarker and anticancer agent development. Semin Oncol. 2017; 44(3):198-203. PMC: 5737780. DOI: 10.1053/j.seminoncol.2017.10.004. View

17.

Arendt L, McCready J, Keller P, Baker D, Naber S, Seewaldt V . Obesity promotes breast cancer by CCL2-mediated macrophage recruitment and angiogenesis. Cancer Res. 2013; 73(19):6080-93. PMC: 3824388. DOI: 10.1158/0008-5472.CAN-13-0926. View

18.

Hahn E, Halestrap A, Gamelli R . Expression of the lactate transporter MCT1 in macrophages. Shock. 2000; 13(4):253-60. DOI: 10.1097/00024382-200004000-00001. View

19.

Konig A, Vilsmaier T, Rack B, Friese K, Janni W, Jeschke U . Determination of Interleukin-4, -5, -6, -8 and -13 in Serum of Patients with Breast Cancer Before Treatment and its Correlation to Circulating Tumor Cells. Anticancer Res. 2016; 36(6):3123-30. View

20.

Martinez-Outschoorn U, Sotgia F, Lisanti M . Tumor microenvironment and metabolic synergy in breast cancers: critical importance of mitochondrial fuels and function. Semin Oncol. 2014; 41(2):195-216. DOI: 10.1053/j.seminoncol.2014.03.002. View